Skip to content

About Us
Our Science
Partnerships
News

News
READ THE LATEST UPDATES

October 13, 2023 | Press Releases

Inmagene Doses First Patient in Phase 2a Trial of IMG-007, an Anti-OX40 Monoclonal Antibody with an Extended Half-life, for the Treatment of Alopecia Areata

September 21, 2023 | Press Releases

Inmagene announces formation of Celexor Bio based on its anti-ILT7 mAb with enhanced pDC depletion function

August 18, 2023 | Press Releases

Inmagene’s anti-OX40 mAb demonstrated an extended half-life and a favorable safety profile in a Phase I study

5

About Us
Our Science
Partnerships
News

About Us
Our Science
Partnerships
News

Copyright © 2025 Miragene All Rights Reserved

Company

About Us
Our Science
Pipeline
Partnerships
Contact Us

Scroll to Top